臨床試驗(yàn)質(zhì)量管理體系文件，包括質(zhì)量手冊(cè)、程序文件、標(biāo)準(zhǔn)操作規(guī)程（SOP）和標(biāo)準(zhǔn)化表格；符合2020版GCP法規(guī)要求。源于申辦方/藥廠，非CRO。如果只有SOP和標(biāo)準(zhǔn)化表格也可以。   [更多]

需求的內(nèi)容在上傳的附件里   [更多]

本集團(tuán)擬收購(gòu)一藥廠或混懸劑、顆粒劑、注射劑文號(hào)。 藥廠需要提供土地面積，批文數(shù)量，大致報(bào)價(jià)。 以江浙最佳，海南，廣東亦可。 希望是藥智數(shù)據(jù)庫(kù)里面沒有的項(xiàng)目。有轉(zhuǎn)讓意向且尚未轉(zhuǎn)讓的，可提供藥廠具體負(fù)責(zé)轉(zhuǎn)讓事宜的聯(lián)系人及聯(lián)系方式。 不要中介！   [更多]

1. Miller J. Ogidigben, Teh-Ching Chu and David E. Potter. Naphazoline-induced neuroendocrine changes Increases in ANP and cGMP levels 2. Robert J. Dockhorn and Thomas G. Duckett. Comparison of Naphcon-A and Its components 3. Mark B, Abelson MD, Salim I, et al. Tolerance and absence of rebound vasodilation following topical ocular decongestant usage 4. Ogidigben MJ, Chu TC, Potter DE. Naphazoline-induced suppression of aqueous humor pressure and flowinvolvement of central and peripheral alpha(2) I(1) receptors 5. The efficacy of long-term treatment with Tolvaptan to prolong the time until dialysis initiation in patients with chronic kidney disease and heart failure 6. Renoprotective effects of tolvaptan in hypertensive heart failure rats depend on renal decongestion 7. Tolvaptan Efficiently Reduces Intracellular Fluid Working Toward a Potential Treatment Option for Cellular Edema 8. Analysis of tolvaptan non-responders and outcomes of tolvaptan treatment of ascites 9. Tolvaptan in Japanese patients with later-stage autosomal dominant polycystic kidney disease 10. Safety and Effectiveness of Tolvaptan Administration after Total Arch Replacement 11. Nephrol Dial Transplant. 2018 Oct 12. doi 10.1093ndtgfy297. [Epub ahead of print] 12. Nephrol Dial Transplant. 2018 Oct 11. doi 10.1093ndtgfy298. [Epub ahead of print] 13. Development and validation of RP-HPLC method for simultaneous estimation of Ofloxacin and Ornidazole inpresence of Ornidazole Impurity in combined pharmaceutical dosage form 14. Stability-indicating methods for the determination of Ornidazole in the presence of its degradate according to ICH guidelines 15. A sensitive HPLC method of determination of 2-methyl 5-nitro imidazole & reaction mass of intermediates of ornidazole in ornidazole bulk manufacturing 16. Development and validation of a reversed-phase HPLC method for the analysis of ornidazole in pharmaceutical dosage forms 17. On the hydrolytic behavior of tinidazole, metronidazole,   [更多]

標(biāo)題： 1、Morisset M et al. Allergy to cow milk proteins contaminating lactose, common excipient of dry powder inhalers for asthma. J Allergy Clin Immunol 2006; 117(Suppl. 1): 95 2、Safety and tolerability of selumetinib as a monotherapy, or in combination with docetaxel as second-line therapy, in Japanese patients with advanced solid malignancies or non-small cell lung cancer. 3、Preparation and characterization of a cocrystalline suspension of [LysB28,ProB29]-human insulin analogue. DeFelippis MR1, Bakaysa DL, Bell MA, Heady MA, Li S, Pye S, Youngman KM, Radziuk J, Frank BH 1、Heterocycles, 2001 , vol. 55, # 2 p. 331 - 352 4、R. G. Strickley, L. Liu, and P. Lapresca. Preclinical parenteral and oral formulations of water insoluble molecules. ISSX Meet- ing, Nashville, TN (USA) Abstract # 291 (1999). (Z) 5、465: A possible genetic signature of DNA repair genes in triple negative breast cancers by a NGS approach 4、Systemic exposure to?atorvastatin?between Asian and Caucasian subjects: a combined analysis of 22 studies. 6、 Evaluation of cardiovascular morbidity associated with adherence to?atorvastatin?therapy. 7、Beta-lactam antibiotics: their role in the management of infections in children 8、China type 2 diabetes treatment status survey of treatment pattern of oral drugs users. J Diabetes. 2015 Mar;7(2):166-73 9、Non‐steroidal anti‐inflammatory drugs and upper gastrointestinal bleeding, a post‐marketing surveillance case‐control study 10、Individual nonsteroidal antiinflammatory drugs and other risk factors for upper gastrointestinal bleeding and perforation. 備注：將符合要求文獻(xiàn)的PDF格式打包上傳   [更多]

標(biāo)題： 1、PMID：29241352 Rhabdomyolysis and elevated liver enzymes after rapid correction of hyponatremia due to pneumonia and concurrent use of aripiprazole: a case report 2、PMID：18306096 Hyponatremia in psychiatric patients: update on evaluation and management 3、PMID：20643634 The assessment and treatment of water imbalance in patients with psychosis 4、Marí M, Morales A, Colell A, García-Ruiz C, Fernández-Checa JC. Mitochondrial glutathione, a key survival anti-oxidant. Antioxid Redox Signal. (2009) 11(11)2685-700 5、Yeni D;Effect of α-lipoic acid on sperm quality, reproductive tract measures in thinner exposed rats. 6、PRELIMINARY BASELINE DATA OF HYPERTENSIVE PATIENTS INCLUDED IN THE CATCH (CANDESARTAN ASSESSMENT IN THE TREATMENT OF CARDIAC HYPERTROPHY) STUDY: P1.195 7、Synthesis and antibacterial activity of 1-cyclopropyl-6,8-difluoro-7-(2-substituted 4,6-dihydro-1H-pyrrolo[3,4-d]thiazol-5-yl)-1,4-dihydro-4-oxoquinoline-3-carb oxylic acid 8、Steady-state pharmacokinetics of tenofovir disoproxil fumarate in human immunodeficiency virus-infected Chinese patients: Expert Review of Clinical Pharmacology: Vol 10, No 7 9、Bioequivalence study of two oral tablet formulations containing tenofovir disoproxil fumarate in healthy volunteers. - PubMed - NCBI 10、 Huiming Ma.Protective function of alpha-lipoic acid on sperm motility and mitochondrial function during goat sperm-mediated gene transfer[J].Small Ruminant Research 99 (2011) 191-198 11、The safety of medical devices containing DEHP plasticized PVC or other plasticizers on neonates and other groups possibly at risk (2015 update). 12、Mechanisms of recognition of amyloid-β (Aβ) monomer, oligomer, and fibril by homologous antibodies. 將符合標(biāo)題的文獻(xiàn)PDF格式上傳，按照交稿時(shí)間的先后確認(rèn)稿件，先到先得   [更多]

求購(gòu)睪酮凝膠進(jìn)口藥品注冊(cè)信息：JX20250149   [更多]

我司誠(chéng)意求購(gòu)硫酸氫氯吡格雷原料藥項(xiàng)目，尋求該原料藥完整技術(shù)轉(zhuǎn)讓，登記狀態(tài)無(wú)特殊要求，具備商業(yè)化可落地成熟項(xiàng)目，并要求聯(lián)系方式真實(shí)有效。支付要求：我方打電話確認(rèn)對(duì)方有轉(zhuǎn)讓意向即可支付賞金，如果能進(jìn)一步牽線達(dá)成轉(zhuǎn)讓目標(biāo)則另有重金酬謝。   [更多]

我司誠(chéng)意求購(gòu)吲哚布芬原料藥項(xiàng)目，尋求該原料藥完整技術(shù)轉(zhuǎn)讓，登記狀態(tài)無(wú)特殊要求，具備商業(yè)化可落地成熟項(xiàng)目，并要求聯(lián)系方式真實(shí)有效。支付要求：我方打電話確認(rèn)對(duì)方有轉(zhuǎn)讓意向即可支付賞金，如果能進(jìn)一步牽線達(dá)成轉(zhuǎn)讓目標(biāo)則另有重金酬謝。   [更多]

急需冷敷凝膠、液體敷料及醫(yī)用冷敷貼的一類醫(yī)療器械全套備案申請(qǐng)資料各一套。具體包括： 產(chǎn)品風(fēng)險(xiǎn)分析報(bào)告、產(chǎn)品技術(shù)要求、產(chǎn)品檢驗(yàn)報(bào)告、臨床評(píng)價(jià)資料、產(chǎn)品說(shuō)明書及標(biāo)簽樣稿、與產(chǎn)品研制、生產(chǎn)有關(guān)的質(zhì)量管理體系文件、生產(chǎn)制造信息、符合性聲明   [更多]